- Trials with a EudraCT protocol (83)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
83 result(s) found for: Hepatic artery.
Displaying page 3 of 5.
EudraCT Number: 2012-002478-30 | Sponsor Protocol Number: FLUSH | Start Date*: 2013-06-05 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Arterial perfusion with t-PA in donation after cardiac death (DCD) to reduce the incidence of non-anastomotic biliary strictures after orthotopic liver transplantation | ||
Medical condition: Biliary strictures after orthotopic liver transplantation caused by microthrombi in the donorliver during procurement | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000505-39 | Sponsor Protocol Number: CHUBX2014/13 | Start Date*: 2015-03-19 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: The role of dexchlorpheniramine (Polaramine®) to prevent hemodynamic instability after separation from cardiopulmonary bypass during cardiac surgery. | |||||||||||||
Medical condition: vasoplegic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014593-18 | Sponsor Protocol Number: CT-2008-01 | Start Date*: 2009-12-07 | |||||||||||
Sponsor Name:CureTech | |||||||||||||
Full Title: CT-2008-01: Phase II study to evaluate the safety, tolerability and efficacy of FOLFOX + CT-011 versus FOLFOX alone administered intravenously to patients with colorectal adenocarcinoma previously ... | |||||||||||||
Medical condition: This study will enroll patients with untreated, metastatic colorectal carcinoma who are eligible for first line FOLFOX therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017843-32 | Sponsor Protocol Number: LOL-III-1 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:Foundation of Liver Research (SLO) | |||||||||||||
Full Title: A multi-center randomized, open label, controlled study in primary liver transplantation comparing long term renal function and development of de novo malignancy in recipients treated with standard... | |||||||||||||
Medical condition: Liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001593-18 | Sponsor Protocol Number: 958 | Start Date*: 2015-06-02 |
Sponsor Name:Medizinische Universiät Wien | ||
Full Title: A pilot study to assess the influence of drug transporters on brain and organ distribution of erlotinib in humans | ||
Medical condition: Investigation in volunteers only | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000128-16 | Sponsor Protocol Number: 2011-003 | Start Date*: 2012-07-30 | |||||||||||
Sponsor Name:Onyx Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000345-46 | Sponsor Protocol Number: CRC2017_01 | Start Date*: 2017-11-22 | |||||||||||
Sponsor Name:CENTRO RICERCHE CLINICHE DI VERONA | |||||||||||||
Full Title: A Phase II Study of Liposomial IrinoTecan (nal-IRI) with 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer ¿nITRo trial" | |||||||||||||
Medical condition: Resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000614-64 | Sponsor Protocol Number: VIRUSNET201401 | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University | |||||||||||||
Full Title: Study of recombinant adenovirus in patients with neuroendocrine neoplasms; safety and efficacy | |||||||||||||
Medical condition: Neuroendocrine neoplasms (NENs) is a heterogeneous group with varying symptoms, tumor biology and treatment response. NENs may occur in any organ, most commonly they are observed in the gastroente... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003894-26 | Sponsor Protocol Number: 1160.26 | Start Date*: 2005-12-23 |
Sponsor Name:Boehringer Ingelheim AB | ||
Full Title: Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke... | ||
Medical condition: Prevention of Stroke and Systemic Embolism in patients with Atrial Fibrillation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) FI (Completed) CZ (Completed) AT (Completed) HU (Completed) DE (Completed) SK (Completed) IT (Completed) ES (Completed) GB (Completed) PT (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003177-99 | Sponsor Protocol Number: A3921133 | Start Date*: 2014-07-10 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SE (Completed) FI (Completed) NL (Completed) SK (Completed) GB (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000935-27 | Sponsor Protocol Number: 0468H1-313-EU | Start Date*: 2005-06-15 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.Clinical Research & Development Department | ||
Full Title: A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipi... | ||
Medical condition: Liver allograft recipients under maintenance therapy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003144-23 | Sponsor Protocol Number: PANDA | Start Date*: 2014-02-03 | |||||||||||||||||||||
Sponsor Name:King's College London [...] | |||||||||||||||||||||||
Full Title: Pregnancy And chronic hypertension: NifeDipine or labetalol as Antihypertensive treatment | |||||||||||||||||||||||
Medical condition: Chronic hypertension in pregnancy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017082-39 | Sponsor Protocol Number: Bay 58-2667 / 14836 | Start Date*: 2010-02-01 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 μg/h, 100 μg/h, 150 μg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002803-37 | Sponsor Protocol Number: XC001-1001 | Start Date*: 2022-01-20 | |||||||||||
Sponsor Name:XyloCor Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic ... | |||||||||||||
Medical condition: Angina Pectoris Secondary | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001067-36 | Sponsor Protocol Number: 18588 | Start Date*: 2016-11-21 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosp... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) GR (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002208-21 | Sponsor Protocol Number: TP-434-025 | Start Date*: 2016-09-27 | |||||||||||
Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Meropenem in Complicated Intra-abdominal Infections | |||||||||||||
Medical condition: Complicated Intra-abdominal Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) LV (Completed) EE (Completed) LT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003482-68 | Sponsor Protocol Number: BAY 63-2521/12934 | Start Date*: 2008-11-26 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptom... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IE (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) FR (Completed) SE (Completed) GB (Completed) CZ (Completed) DK (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001853-89 | Sponsor Protocol Number: CLI-043 | Start Date*: 2006-07-07 |
Sponsor Name:Vion Pharmaceuticals, Inc | ||
Full Title: A phase II study of Cloretazine for elderly patients with de novo poor risk acute myelogenous leukemia. | ||
Medical condition: Acute Myelogenous Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002120-33 | Sponsor Protocol Number: HLSCS01-11 | Start Date*: 2013-12-06 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA | ||||||||||||||||||||||||||||
Full Title: Human Liver Stem Cells (HLSCs) in patients suffering from liver-based inborn metabolic diseases causing life-threatening neonatal onset of hyperammonemic encephalopathy | ||||||||||||||||||||||||||||
Medical condition: neonatal hyperammonemic encephalopathy associated with inborn liver metabolic diseases | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002802-30 | Sponsor Protocol Number: GS-US-337-0124 | Start Date*: 2014-03-12 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who ha... | |||||||||||||
Medical condition: Chronic Genotype 1 and Genotype 4 Hepatitis C Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) IT (Completed) AT (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
